Clinical Trial Update: Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment [Phase 3]

View source ↗

Summary

Phase 3 safety and pharmacokinetics study of DU-176b in non-valvular atrial fibrillation patients with severe renal impairment has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-valvular Atrial Fibrillation

Drugs mentioned

• DU-176b

Snippet

Sponsor: Daiichi Sankyo Co., Ltd. | Conditions: Non-valvular Atrial Fibrillation | Phase 3 | Status: COMPLETED | Results posted: 2015-01-26